Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.4.21.5 (thrombin)
33,306 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have extended our earlier observation that growing primary cultures of human umbilical vein endothelial cells (HUVEC) with heparin binding growth factor 1 (HBGF-1) 20 micrograms/mL and heparin 12 U/mL inhibits expression of tissue factor (TF) activity on HUVC monolayers perturbed with thrombin. TF activity was measured as the ability of monolayers or cell lysates to support FVIIa-catalyzed activation peptide release from 3H-FX. TF antigen in HUVEC extracts was measured in an enzyme-linked immunosorbent assay (ELISA) that uses a double-antibody sandwich technique with rabbit and goat antibodies to human TF. TF-mRNA was measured by Northern blot hybridization with a 32P-TF cDNA probe. Cells growth with HBGF-1/heparin had both decreased surface and total TF activity as compared with HUVEC from the same endothelial cell pool grown without HBGF-1/heparin. Means +/- SD for TF antigen for four primary cultures were 4.4 +/- 0.9 ng/10(6) cells without HBGF-1/heparin and 0.6 +/- 0.3 ng/10(6) cells with HBGF-1/heparin. TF mRNA 4 hours after incubation with thrombin of HUVEC grown without HBGF-1/heparin was about sevenfold higher than TF mRNA of HUVEC grown with HBGF-1/heparin. These data establish that growing primary cultures of HUVEC with HBGF-1/heparin impairs their ability to synthesize TF apoprotein after perturbation. This may be part of a generalized response of endothelial cells to HBGF-1/heparin facilitating migration during angiogenesis.
...
PMID:Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin. 170 37

Although it is well established that calcium is an essential cofactor in blood coagulation, recent experimental evidence suggests that zinc may also play an important role in hemostasis. In the present study, we have examined the effect of zinc ions on the amidolytic and proteolytic activity of recombinant factor VIIa in the presence of physiological levels of calcium ions. The amidolytic activity of factor VIIa was inhibited half-maximally by 20 microM zinc. The amidolytic activity of a derivative of factor VIIa lacking the gamma-carboxyglutamic acid domain was also inhibited half-maximally by 20 microM zinc, suggesting that the mechanism of zinc inhibition of factor VIIa amidolytic activity did not involve its gamma-carboxyglutamic acid residues. The amidolytic activity of a complex of recombinant tissue factor and factor VIIa was inhibited half-maximally by 70 microM zinc. In contrast to the results obtained with factor VIIa, the amidolytic activities of other human vitamin K-dependent coagulation proteases including factor Xa, thrombin and activated protein C were not appreciably affected by 50-100 microM zinc. The proteolytic activation of factor X by a complex of factor VIIa and relipidated tissue factor apoprotein was inhibited half-maximally by 40 microM zinc, whereas activation of factor IX in this system was inhibited half-maximally by 70 microM zinc ions. Considerably higher levels of zinc (approximately 100 microM) were required to inhibit half-maximally the rate of factor X activation by a complex of factor VIIa and functional tissue factor on the surface of either a human bladder carcinoma cell line, J82, or stimulated human umbilical vein endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions. 187 14

There is agreement about the influence of the genetic apolipoprotein (apo E) polymorphism on plasma lipid and apoprotein levels in man. Whereas the association of the apo E2 isoform with primary dysbetalipoproteinemia and hyperlipoproteinemia type III is well established, the plasma- and LDL-cholesterol lowering effects of apo E2 and the phenomenon of apo E4 raising these parameters on the development of coronary heart disease is still a matter of controversial discussion. Despite these uncertainties the knowledge of an individual's apo E phenotype may provide additional information in future to judge its risk to develop atherosclerosis. From a variety of methods meanwhile described to analyze the polymorphism and evaluate the apo E phenotype the author has modified three procedures to apply to different questions concerning apo E isoform analysis. They concern the visualization of the apo E pattern in diluted solutions and those containing high salt concentrations, the apo E phenotyping on a large scale basis from whole plasma avoiding a possible misinterpretation by a thrombin fragment of apo E and finally the search for new apo E variants with a high resolution system on immobilized pH gradient gels.
...
PMID:Clinical implications of the apolipoprotein E polymorphism and genetic variants: current methods for apo E phenotyping. 204 69

Low density lipoproteins (LDL) were modified after incubation with fibrinogen and fibronectin at physiological concentrations in presence of thrombin and, following the fibrin formation, in presence of plasmin. The modified LDL (LDL-F) isolated from plasmin digested fibrin by means of gel permeation chromatography on Sepharose 6B, were associated with fibrinogen and fibronectin degradation products. The LDL-F differed from control LDL in their physico-chemical properties: LDL-F contained the degraded apoprotein B, its electrophoretic mobility was increased, cholesterol/protein ratio as well as flotation coefficient at d = 1.063 were decreased. The effect of LDL-F on lipid accumulation was studied. Content of cholesterol esters in macrophages incubated with LDL-F was higher 3.8-fold as compared with that of the cells incubated with control LDL. Thus, after incubation of LDL with fibrinogen and thrombin, 20% of the lipoprotein was bound to fibrin. The data obtained suggest that thrombosis may promote both LDL deposition in the vascular intercellular matrix and cellular lipid accumulation.
...
PMID:[Atherogenic modifications of low density lipoproteins during fibrin formation and fibrinolysis]. 274 16

Apolipoprotein (apo) B-100, the protein constituent of low density lipoproteins (LDL), is the determinant responsible for LDL binding to the apoB,E(LDL) receptor on cells. The current study was designed to identify the region(s) of apoB-100 that interact with the apoB,E(LDL) receptor. Apolipoprotein B-100 was fragmented by thrombin digestion, and the isolated fragments (T2, T3, T4) were recombined with cholesterol-induced canine high density lipoproteins (HDLc). Before the recombination, the receptor binding activity of apoE of the HDLc was abolished by reductive methylation and extensive trypsin treatment. This treatment permitted almost complete replacement of the small residual apoE fragments by the large apoB fragments. Recombinant apoB particles were isolated by ultracentrifugation and tested for binding to receptors on cultured human fibroblasts. The recombinant particles had chemical and physical properties similar to those of native HDLc. Recombinants of both the whole thrombolytic digest and of isolated fragments displayed specific binding to the apoB,E (LDL) receptor. Anti-apoB,E(LDL) receptor antibodies abolished 90% of the binding, and there was almost no specific binding to receptor-negative fibroblasts or to cells in which the receptors had been down-regulated. The binding of apoB-100 recombinants to the receptor also demonstrated calcium dependency; in addition, the surface binding of the recombinants was released by polyanionic compounds. All these recombinants had binding affinities comparable to one another but less than that of native LDL. Although T2, T3 and T4 recombinants can all bind specifically to the apoB,E(LDL) receptor, it remains to be established whether their activity represents physiologically relevant binding. Nevertheless, the present findings illustrate the potential of the recombinant method using HDLc lipids to reconstitute biological activity.
...
PMID:Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments. 282

Thrombomodulin and tissue factor activities have been co-extracted from human placenta by several non-ionic detergents, n-octylglucoside and Triton X-100 being the most efficient ones. The n-octylglucoside placenta extract had a strong cofactor activity in the activation of human protein C by human alpha-thrombin. Treatment of the n-octylglucoside and Triton X-100 placenta extracts by phospholipases C and A2 revealed that an adequate phospholipid environment is necessary for maximal thrombomodulin activity, while it is well known that this is crucial for tissue factor activity. Soluble concanavalin A reversibly inhibited thrombomodulin and tissue factor activities to the same extent. Con-A-Sepharose affinity chromatography of the Triton X-100 placenta extract resulted in the same proportion (30%) of these two activities bound to the lectin, which were subsequently eluted in the same fractions by a linear gradient of alpha-methyl-D-glucoside. This observation suggests that thrombomodulin activity is associated to a glycoprotein component presenting the same degree of carbohydrate heterogeneity, involving alpha-D-mannosyl or alpha-D-glucosyl residues, as tissue factor apoprotein. Relipidation of fraction eluted by alpha-methyl-D-glucoside was essential to detect tissue factor activity, it was also necessary to recover full thrombomodulin activity. An antibody to human brain tissue factor apoprotein inhibited human placenta tissue factor activity, whereas thrombomodulin activity was unaffected, suggesting that these two cellular activities are related to distinct molecular entities sharing striking functional and structural similarities.
...
PMID:Coextraction of thrombomodulin and tissue factor from human placenta: effects of concanavalin A and phospholipid environment on activity. 301 Apr 87

HTG-VLDL1, like LDL, bind with high affinity to electrophoretically transferred, isolated LDL receptors partially purified from bovine adrenal glands. Ligand blotting techniques show that binding is calcium dependent; little or no binding of LDL or HTG-VLDL1 is observed in the presence of 10 mM EDTA. HTG-VLDL1 does not bind in the presence of 7 mM suramin, an inhibitor of LDL binding to the LDL receptor. Pretreatment of LDL with either thrombin or trypsin does not affect apoB-mediated LDL binding to the LDL receptor. ApoE-mediated binding of HTG-VLDL1 to the blotted LDL receptor is abolished or greatly decreased by thrombin treatment of HTG-VLDL1; trypsin treatment of HTG-VLDL1 abolishes binding. Reincorporation of apoE into trypsinized HTG-VLDL1 restores binding. These studies demonstrate unequivocally that HTG-VLDL1 bind to the LDL receptor, that the binding of HTG-VLDL1 to the isolated LDL receptor is mediated through the thrombin-accessible apoE, and that HTG-VLDL1 which bind via potentially dissociable apoE rather than non-transferable apoB can be used for ligand blotting.
...
PMID:Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting. 309 11

Very low density lipoproteins Sf 100-400 (VLDL1) from hypertriglyceridemic (HTG) subjects and chylomicrons cause receptor-mediated lipid engorgement in unstimulated macrophages in vitro via the beta-VLDL receptor pathway. We now report that the murine macrophage P388D1 cell line possesses the characteristics of the beta-VLDL receptor pathway observed previously in freshly isolated resident murine peritoneal macrophages or human monocyte-macrophages. HTG-VLDL1 isolated from the plasma of subjects with hypertriglyceridemia types 3, 4, and 5 interact with P388D1 macrophages in a high-affinity, curvilinear manner. beta-VLDL, HTG-VLDL1, chylomicrons, and thrombin-treated HTG-VLDL1 (which do not bind to the LDL receptor) compete efficiently and similarly for the uptake and degradation of HTG-VLDL1. LDL and acetyl LDL do not compete, indicating that uptake of HTG-VLDL1 is via neither the LDL receptor nor the acetyl LDL receptor. Binding of thrombin-treated HTG-VLDL1 to the beta-VLDL receptor indicates that the thrombin-accessible apoE, which is absolutely required for interaction of HTG-VLDL Sf greater than 60 with the LDL receptor, is not required for binding to the beta-VLDL receptor. The uptake and degradation of 125I-labeled HTG-VLDL1 is suppressed up to 80-90% by preincubation of the cells with sterols, acetyl LDL, or beta-VLDL, indicating that this process is not via the irrepressible chylomicron remnant (apoE) receptor. Chylomicrons, HTG-VLDL1, and thrombin-treated HTG-VLDL1-but not normal VLDL1, beta-VLDL, LDL, or acetyl LDL-produce massive triglyceride accumulation (10-20-fold mass increases in 4 hr) in P388D1 macrophages.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The beta-VLDL receptor pathway of murine P388D1 macrophages. 372 14

Interaction of native and thrombin-modified human low density lipoproteins (LDL) with immobilized homologous fibronectin (either covalently bound to Sepharose or adsorbed from blood serum on collagen-Sepharose) was studied. Treatment of LDL with thrombin at pH 7.5 and 37 degrees within 60 min (thrombin/apo B ratio 1:20 w/w) led to formation in LDL preparations of 3 new fragments of apoprotein B which were detected by polyacrylamide gel electrophoresis in presence of sodium dodecylsulfate. Chromatography of native and thrombinmodified LDL on fibronectin-Sepharose showed that 30% of the modified LDL and 2% of native LDL were bound to fibronectin-Sepharose at physiological pH values and NaCl concentrations. Study of the interaction of LDL with fibronectin adsorbed on collagen-Sepharose showed that thrombin-treated LDL partially released fibronectin from the sorbent due to the formation of a modified LDL-fibronectin complex. Native LDL did not act in a similar manner. Complexes of modified, LDL with fibronectin were detected under conditions of both electrophoresis in 3% polyacrylamide gel and immunoelectrophoresis. Interaction of LDL with fibronectin may promote accumulation of lipoproteins in the vascular wall and thus may serve as a model system for evaluation of the extent of atherogeneity of LDL and detection of the modified LDL in vivo.
...
PMID:[Effect of the modification of low density lipoproteins by thrombin on their interaction with fibronectin]. 381 Dec 92

We have used both proteolysis and reconstitution experiments to characterize the determinants for LDL receptor binding of HTG-VLDL. In these studies, we showed that the removal of approximately one mole of apo E per mole of HTG-VLDL (Sf 100-400) and HTG-VLDL (Sf 60-100) by thrombin-specific cleavage results in loss of receptor binding and concomitant loss of suppression of HMG-CoA reductase. This is in direct contrast to the lack of effect thrombin cleavage has on the receptor-mediated uptake of LDL, an apo B-mediated process. We were able to reconstitute receptor binding in thrombin-treated HTG-VLDL (Sf 100-400) by the specific reincorporation of one mole of apo E into the VLDL. The incorporation of one mole of apo E into normal non-suppressive VLDL (Sf 60-400) also enables this lipoprotein to bind to the receptor as effectively as LDL. Trypsin, which destroys apo E-mediated, but not apo B-mediated binding to the LDL receptor, abolishes binding of HTG-VLDL (Sf 100-400) and HTG-VLDL (Sf 60-100), but not that of HTG-VLDL (Sf 20-60), IDL, or LDL to the LDL receptor. Therefore, we conclude that apo E of the appropriate conformation is required for receptor-mediated uptake by the LDL receptor of large TG-rich lipoproteins (Sf greater than 60). This conformation of apo E is probably related to the surface on which it is found (i.e., size of the particle) and the mode of incorporation into the phospholipid surface (i.e., transferred from plasma HDL). In large TG-rich particles, it appears that the intact apo E is necessary for the proper orientation of the molecule on the surface, with the carboxy-terminal one-third needed to anchor the apoprotein to the phospholipid surface. We believe that the binding of apo E to the LDL receptor is a redundant system and is used as a backup system in abnormal pathological states such as hypertriglyceridemia, abetalipoproteinemia, and hypobetalipoproteinemia. In the case of hypertriglyceridemia, where the lipolysis mechanism is overloaded, the abnormal binding of HTG-VLDL (Sf greater than 60) provides an alternate catabolic route for their removal from plasma. In the cases of a beta- and hypobetalipoproteinemia, where the normal particles for cholesterol delivery are either absent or at low levels, apo E-containing particles can serve to deliver cholesterol to cells as has been recently observed in vitro.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Expression of LDL receptor binding determinants in very low density lipoproteins. 390 64


1 2 3 4 5 Next >>

---